The Relative Strength (RS) Rating for Alnylam Pharmaceuticals headed into a higher percentile Wednesday morning, as it got a lift from 63 to 71.
When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.
This exclusive rating from Investor's Business Daily identifies market leadership with a 1 (worst) to 99 (best) score. The score shows how a stock's price movement over the last 52 weeks compares to all the other stocks in our database.
Decades of market research shows that the stocks that go on to make the biggest gains tend to have an 80 or better RS Rating as they begin their biggest price moves. See if Alnylam Pharmaceuticals can continue to rebound and clear that threshold.
Looking For The Best Stocks To Buy And Watch? Start Here
While it's not currently an ideal time to jump in, see if the stock goes on to establish and enter a buying range in heavy volume.
Earnings News
EPS growth fell last quarter from 0% to -5%, but sales rose from 49% to 58%. The next quarterly results are expected on or around Apr. 29.
Alnylam Pharmaceuticals stock earns the No. 75 rank among its 796 peers in the large Medical-Biomed/Biotech industry group. Pacira Pharmaceuticals and Regeneron Pharmaceutical are also among the group's highest-rated stocks.
Stocks To Buy And Watch: Top IPOs, Big And Small Caps, Growth Stocks
